Skip to main content
SpringerLink
Log in

Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Purpose

Contrast-enhanced CT (CECT) is a standard investigative procedure in the localization of gastrinomas. Small tumors are often missed and metastatic lesions may remain occult on CT. The purpose of present study was to prospectively evaluate the diagnostic performance of 68Ga-labeled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-NaI3-Octreotide (68Ga-DOTANOC) positron emission tomography/computed tomography (PET/CT) in gastrinoma patients with negative or equivocal CT findings.

Methods

Twenty-five patients (age 46.6 ± 13.3 years; male 60%) with clinical/biochemical diagnosis of gastrinoma and negative or equivocal findings on CECT were prospectively evaluated. All of them underwent 68Ga-DOTANOC PET/CT which was evaluated by two nuclear medicine physicians in consensus. Combination of histopathology, serum gastrin, endoscopy, and follow-up imaging were taken as reference standard.

Results

68Ga-DOTANOC PET/CT was positive in 17 patients and negative in 8 patients, yielding an overall detection rate of 68%. It was positive 13/20 patients who underwent baseline evaluation and in 4/5 post-treatment patients. Of the 11 patients who had a negative CT result, 68Ga-DOTANOC PET/CT was positive in four cases (detection rate 36.4%), while it was abnormal in 13/14 patients who had equivocal CT findings (detection rate 92.8%). Diagnostic performance of 68Ga-DOTANOC PET/CT was superior in patients with equivocal CECT findings than that in patients with negative CECT (P = 0.010).

Conclusion

68Ga-DOTANOC PET/CT appears to be useful in patients with gastrinoma with negative or equivocal results on CECT, especially the latter group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wise SR, Johnson J, Sparks J, et al. (1989) Gastrinoma: the value of preoperative localization. Surgery 106:1087–1093

    PubMed  CAS  Google Scholar 

  2. Frucht H, Doppman JL, Norton JA, et al. (1989) MR imaging of gastrinomas: comparison with computed tomography, angiography and ultrasound. Radiology 171:713–717

    PubMed  CAS  Google Scholar 

  3. Imamura M, Takahasi K, Adachi H, et al. (1987) Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger–Ellison syndrome. Ann Surg 205:230–239

    Article  PubMed  CAS  Google Scholar 

  4. Rosch T, Lightdale CJ, Botet JF (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326:1721–1726

    Article  PubMed  CAS  Google Scholar 

  5. Kvols LK (1993) Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. Gastroenterology 105:1909–1914

    PubMed  CAS  Google Scholar 

  6. de Kerviler E, Cadiot G, Lebtahi R, et al. (1994) Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger–Ellison syndrome. GRESZE: groupe d’Etude du syndrome de Zollinger–Ellison. Eur J Nucl Med 21:1191–1197

    Article  PubMed  Google Scholar 

  7. Gibril F, Reynolds JC, Doppman JL, et al. (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26–34

    Article  PubMed  CAS  Google Scholar 

  8. Antunes P, Ginj M, Zhang H, et al. (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993

    Article  PubMed  CAS  Google Scholar 

  9. Buchmann I, Henze M, Engelbrecht S, et al. (2007) Comparison of 68 Ga-DOTATOC PET and 111In-DTPAOC (octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626

    Article  PubMed  CAS  Google Scholar 

  10. Kowalski J, Henze M, Schuhmacher J, et al. (2003) Evaluation of positron emission tomography imaging using 68Ga-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42–48

    Article  PubMed  Google Scholar 

  11. Gabriel M, Decristoforo C, Kendler D, et al. (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508–518

    Article  PubMed  CAS  Google Scholar 

  12. Naswa N, Sharma P, Kumar A, et al. (2011) Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 197:1221–1228

    Article  PubMed  Google Scholar 

  13. Kumar R, Sharma P, Garg P, et al. (2011) Role of (68)Ga-DOTATOC PET–CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408–2416

    Article  PubMed  Google Scholar 

  14. Versari A, Camellini L, Carlinfante G, et al. (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 35:321–328

    Article  PubMed  Google Scholar 

  15. Zhernosekov KP, Filosofov DV, Baum RP, et al. (2007) Processing of generator-produced 68Ga for medical application. J Nucl Med 48:1741–1748

    Article  PubMed  CAS  Google Scholar 

  16. Ambrosini V, Campana D, Bodei L, et al. (2010) 68Ga-DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669–673

    Article  PubMed  Google Scholar 

  17. Naswa N, Sharma P, Kumar A, et al. (2012) 68Ga DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med 37:245–251

    Article  PubMed  Google Scholar 

  18. Norton JA, Doppman JL, Jensen RT (1992) Curative resection in Zollinger–Ellison syndrome: results of a 10-year prospective study. Ann Surg 215:8–18

    Article  PubMed  CAS  Google Scholar 

  19. Fraker DL, Norton JA, Alexander HR, et al. (1994) Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220:320–330

    Article  PubMed  CAS  Google Scholar 

  20. Stabile BE, Passaro E Jr (1985) Benign and malignant gastrinoma. Am J Surg 49:144–150

    Article  Google Scholar 

  21. Weber HC, Venzon DJ, Lin JT, et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger–Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649

    Article  PubMed  CAS  Google Scholar 

  22. Ellison EH, Wilson SD (1964) The Zollinger–Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 160:512–530

    Article  PubMed  CAS  Google Scholar 

  23. Putzer D, Gabriel M, Henninger B, et al. (2009) Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50:1214–1221

    Article  PubMed  Google Scholar 

  24. Jensen RT (1996) Gastrinoma. Bailliere’s Clin Gastroenterol 10:603–643

    Article  CAS  Google Scholar 

  25. Banasch M, Schmitz F (2007) Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr 119:573–578

    Article  PubMed  CAS  Google Scholar 

  26. Jais P, Mignon M (1995) Normal serum gastrin concentration in gastrinoma. Lancet 346:1421–1422

    Article  PubMed  CAS  Google Scholar 

  27. Yanda RJ, Ostroff JW, Ashbaugh CD, et al. (1989) Zollinger–Ellison syndrome in a patient with normal screening gastrin level. Dig Dis Sci 34:1929–1932

    Article  PubMed  CAS  Google Scholar 

  28. Wolfe MM, Jain DK, Edgerton JR (1985) Zollinger–Ellison syndrome associated with persistently normal fasting serum gastrin concentrations. Ann Intern Med 103:215–217

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Niraj Naswa, Punit Sharma, Ramya Soundararajan, Sellam Karunanithi, Aftab Hasan Nazar, Rakesh Kumar, Arun Malhotra & Chandrasekhar Bal

Authors
  1. Niraj Naswa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Punit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramya Soundararajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sellam Karunanithi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aftab Hasan Nazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rakesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arun Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chandrasekhar Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chandrasekhar Bal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naswa, N., Sharma, P., Soundararajan, R. et al. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging 38, 552–560 (2013). https://doi.org/10.1007/s00261-012-9925-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-012-9925-z

Keywords

Search

Navigation